|
LT2931752T
(lt)
|
2012-12-17 |
2019-12-10 |
Trillium Therapeutics Inc |
Ligos cd47+ ląstelių gydymas su sirp alfa-fc junginiais
|
|
KR20150130349A
(ko)
*
|
2013-03-15 |
2015-11-23 |
메르크 파텐트 게엠베하 |
4가 이중특이적 항체
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
JP6731346B2
(ja)
|
2014-02-10 |
2020-07-29 |
メルク パテント ゲーエムベーハー |
標的ＴＧＦβ阻害
|
|
PT3180363T
(pt)
|
2014-08-15 |
2019-11-05 |
Merck Patent Gmbh |
Proteínas de fusão de sirp-alfa e imunoglobulina
|
|
EP4406604A3
(en)
*
|
2015-03-05 |
2024-10-23 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
RS62151B1
(sr)
|
2015-08-07 |
2021-08-31 |
Alx Oncology Inc |
Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
|
|
WO2017059168A1
(en)
|
2015-10-01 |
2017-04-06 |
Heat Biologics, Inc. |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
|
CN107149682B
(zh)
*
|
2016-03-04 |
2022-01-04 |
复旦大学 |
一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法
|
|
US11649284B2
(en)
*
|
2016-04-18 |
2023-05-16 |
Baylor College Of Medicine |
Cancer gene therapy targeting CD47
|
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
|
CN107459578B
(zh)
*
|
2016-05-31 |
2021-11-26 |
泰州迈博太科药业有限公司 |
一种靶向cd47与pd-l1的双功能融合蛋白
|
|
JP6923942B2
(ja)
*
|
2016-07-05 |
2021-08-25 |
国立大学法人神戸大学 |
抗腫瘍剤
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
AU2017336867B2
(en)
|
2016-09-29 |
2024-03-14 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Heterodimeric immunoglobulin constructs and preparation methods thereof
|
|
BR112019008010A2
(pt)
|
2016-10-20 |
2019-07-09 |
I Mab |
anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
|
|
CA3042583A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
CN106519036B
(zh)
*
|
2016-11-04 |
2019-06-11 |
新乡医学院 |
抗cd47和egfr的双功能蛋白及其制备方法与应用
|
|
MX2019005858A
(es)
|
2016-11-18 |
2019-08-12 |
Beijing Hanmi Pharmaceutical Co Ltd |
Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo.
|
|
CN108220228A
(zh)
*
|
2016-12-09 |
2018-06-29 |
上海迈泰君奥生物技术有限公司 |
无血清细胞培养基及高效表达重组蛋白质的方法
|
|
WO2018127916A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
|
SI3565828T1
(sl)
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
|
|
RU2769513C2
(ru)
|
2017-01-05 |
2022-04-01 |
Кахр Медикал Лтд. |
Слитый белок pd1-4-1bbl и способы его применения
|
|
WO2018127918A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A sirp alpha-cd70 fusion protein and methods of use thereof
|
|
CA3054132A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Csf1r-based chimeric proteins
|
|
AU2018224852B2
(en)
|
2017-02-27 |
2025-03-06 |
Shattuck Labs, Inc. |
VSIG8-based chimeric proteins
|
|
WO2018157165A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Methods of making and using extracellular domain-based chimeric proteins
|
|
CN108623689B
(zh)
*
|
2017-03-15 |
2020-10-16 |
宜明昂科生物医药技术（上海）有限公司 |
新型重组双功能融合蛋白及其制备方法和用途
|
|
MX2019010812A
(es)
|
2017-03-17 |
2019-12-11 |
Hutchinson Fred Cancer Res |
Proteinas de fusion inmunomoduladoras y sus usos.
|
|
CN108864290B
(zh)
*
|
2017-05-08 |
2021-12-07 |
上海津曼特生物科技有限公司 |
双特异性重组蛋白及其应用
|
|
CN111448323B
(zh)
*
|
2017-06-07 |
2023-12-01 |
长源赋能(上海)生命科技有限公司 |
精确制导的多功能治疗抗体
|
|
US11401329B2
(en)
|
2017-08-02 |
2022-08-02 |
Phanes Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
EP3695013A1
(en)
*
|
2017-08-30 |
2020-08-19 |
Symphogen A/S |
Compositions and methods for treating cancer with anti-egfr antibodies
|
|
US11529425B2
(en)
|
2017-09-07 |
2022-12-20 |
Dingfu Biotarget Co., Ltd. |
Immunoconjugates comprising signal regulatory protein alpha
|
|
KR20190037164A
(ko)
*
|
2017-09-28 |
2019-04-05 |
한국과학기술연구원 |
신규 암 치료용 조성물
|
|
WO2019075270A1
(en)
*
|
2017-10-12 |
2019-04-18 |
Amesino Llc |
VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
|
|
CN111278865B
(zh)
*
|
2017-10-26 |
2023-04-25 |
盛禾(中国)生物制药有限公司 |
新的重组融合蛋白及其制备和用途
|
|
WO2019091473A1
(en)
*
|
2017-11-10 |
2019-05-16 |
I-Mab Biopharma Co., Ltd. |
Fusion proteins containing cd47 antibodies and cytokines
|
|
CA3084391C
(en)
*
|
2017-11-20 |
2023-10-10 |
Taizhou Mabtech Pharmaceutical Co., Ltd |
A bifunctional fusion protein targeting cd47 and pd-l1
|
|
EP3722322A4
(en)
|
2017-12-04 |
2021-09-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
ANTI-PD-L1 / ANTI-CD47 BISPECIFIC ANTIBODY HAVING A NATURAL ANTIBODY STRUCTURE AND IN THE FORM OF A HETERODIMER, AND ASSOCIATED PREPARATION
|
|
EP3722312A4
(en)
*
|
2017-12-08 |
2021-07-21 |
Hanx Biopharmaceutics, Inc |
BISPECIFIC ANTI-PD-1 / CD47 ANTIBODIES AND ASSOCIATED APPLICATION
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
JP2021515779A
(ja)
*
|
2018-03-13 |
2021-06-24 |
トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． |
Ｅｇｆｒ抗体によるｃｄ４７遮断療法における改善
|
|
JP7393342B2
(ja)
|
2018-03-21 |
2023-12-06 |
エーエルエックス オンコロジー インコーポレイテッド |
シグナル調節タンパク質αに対する抗体及び使用方法
|
|
CN110386984B
(zh)
*
|
2018-04-17 |
2022-04-22 |
杭州尚健生物技术有限公司 |
结合cd47蛋白的融合蛋白及其应用
|
|
CN108794641A
(zh)
*
|
2018-07-04 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种针对EGFRvIII的多功能融合蛋白及其应用
|
|
US12286466B2
(en)
|
2018-07-11 |
2025-04-29 |
Kahr Medical Ltd. |
PD1-4-1BBL variant fusion protein and methods of use thereof
|
|
WO2020012486A1
(en)
*
|
2018-07-11 |
2020-01-16 |
Kahr Medical Ltd. |
SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
|
|
WO2020029982A1
(en)
|
2018-08-08 |
2020-02-13 |
Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd |
Recombinant bifunctional protein targeting cd47 and her2
|
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
|
AU2019336345A1
(en)
|
2018-09-04 |
2021-04-15 |
Pfizer Inc. |
CD47 blockade with parp inhibition for disease treatment
|
|
CN109535258A
(zh)
*
|
2018-10-26 |
2019-03-29 |
上海科弈药业科技有限公司 |
一种针对Her2+肿瘤的多功能融合蛋白及其应用
|
|
CA3118312A1
(en)
*
|
2018-10-29 |
2020-05-07 |
Tigatx, Inc. |
Compositions and methods comprising iga antibody constructs
|
|
CA3115547A1
(en)
|
2018-11-14 |
2020-05-22 |
Jn Biosciences Llc |
Multimeric hybrid fc proteins for replacement of ivig
|
|
CN111303293B
(zh)
*
|
2018-11-14 |
2022-08-30 |
杭州尚健生物技术有限公司 |
一种融合蛋白及其用途
|
|
BR112021009275A2
(pt)
*
|
2018-11-15 |
2022-01-04 |
Byondis Bv |
Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
|
|
CN109535263B
(zh)
*
|
2018-12-04 |
2022-06-17 |
江苏东抗生物医药科技有限公司 |
SIRPα突变体及其融合蛋白
|
|
CN109517054B
(zh)
*
|
2018-12-04 |
2022-04-08 |
江苏东抗生物医药科技有限公司 |
SIRPα变体或其融合蛋白及其应用
|
|
AU2019409805A1
(en)
|
2018-12-21 |
2021-07-22 |
Ose Immunotherapeutics |
Bifunctional anti-PD-1/SIRPA molecule
|
|
KR20210137477A
(ko)
*
|
2019-03-06 |
2021-11-17 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
이중기능성 융합 단백질 및 그것의 제약학적 용도
|
|
CN111763261B
(zh)
*
|
2019-04-02 |
2022-08-09 |
杭州尚健生物技术有限公司 |
一种融合蛋白及其用途
|
|
TW202045550A
(zh)
*
|
2019-04-05 |
2020-12-16 |
美商西建公司 |
腫瘤選擇性結合cd47之抗體之工程
|
|
EP3976099A1
(en)
|
2019-05-31 |
2022-04-06 |
ALX Oncology Inc. |
Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
|
|
AU2020290962A1
(en)
*
|
2019-06-14 |
2022-02-03 |
The Scripps Research Institute |
Immune checkpoint blocking bispecific molecules
|
|
WO2021004480A1
(zh)
*
|
2019-07-08 |
2021-01-14 |
南京金斯瑞生物科技有限公司 |
抗cd47/抗pd-1双特异抗体及其制备方法和应用
|
|
JP7454645B2
(ja)
|
2019-07-16 |
2024-03-22 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖワクチン並びにその作製方法及び使用方法
|
|
US20220267436A1
(en)
*
|
2019-07-23 |
2022-08-25 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof
|
|
US20220298223A1
(en)
*
|
2019-08-28 |
2022-09-22 |
King's College London |
B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS
|
|
CA3153501A1
(en)
|
2019-10-18 |
2021-04-22 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
CN114599392A
(zh)
|
2019-10-31 |
2022-06-07 |
四十七公司 |
基于抗cd47和抗cd20的血癌治疗
|
|
JP2023500156A
(ja)
*
|
2019-11-08 |
2023-01-04 |
チャンスー シムサー ファーマシューティカル カンパニー リミテッド |
抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途
|
|
PH12022551441A1
(en)
|
2019-12-24 |
2023-11-20 |
Carna Biosciences Inc |
Diacylglycerol kinase modulating compounds
|
|
CR20220396A
(es)
|
2020-02-14 |
2022-11-14 |
Jounce Therapeutics Inc |
Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
|
|
JP2023519346A
(ja)
|
2020-03-27 |
2023-05-10 |
メンドゥス・ベスローテン・フェンノートシャップ |
養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
|
|
CA3182607A1
(en)
|
2020-06-30 |
2022-01-06 |
Erik Hans MANTING |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
CN111808183B
(zh)
*
|
2020-07-25 |
2022-07-08 |
北京吉尔麦迪生物医药科技有限公司 |
一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
|
|
CN116406380A
(zh)
*
|
2020-09-17 |
2023-07-07 |
上海霖羲致企业管理有限公司 |
双特异性重组蛋白及其用途
|
|
JP2023545983A
(ja)
*
|
2020-10-07 |
2023-11-01 |
セルジーン コーポレイション |
リンパ系悪性腫瘍状態の二重特異性抗体治療
|
|
US20220196651A1
(en)
*
|
2020-12-06 |
2022-06-23 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
CN112708675A
(zh)
*
|
2020-12-25 |
2021-04-27 |
中山大学肿瘤防治中心 |
骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
|
|
CN112656941A
(zh)
*
|
2021-01-20 |
2021-04-16 |
福建医科大学附属协和医院 |
抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用
|
|
US20220305100A1
(en)
|
2021-03-12 |
2022-09-29 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
WO2022214652A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
IL308400A
(en)
|
2021-05-13 |
2024-01-01 |
Alx Oncology Inc |
Combined therapies for cancer treatment
|
|
CN117480155A
(zh)
|
2021-06-23 |
2024-01-30 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117377671A
(zh)
|
2021-06-23 |
2024-01-09 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2023003331A1
(en)
*
|
2021-07-19 |
2023-01-26 |
Yuhan Corporation |
Sirp-alpha variants and use thereof
|
|
CN120329453A
(zh)
*
|
2021-07-19 |
2025-07-18 |
百奥泰生物制药股份有限公司 |
基于Luciferase报告基因系统的重组嵌合膜蛋白及其应用
|
|
CN113956363B
(zh)
*
|
2021-10-13 |
2023-03-31 |
宜明昂科生物医药技术（上海）股份有限公司 |
靶向cd47和cd24的重组融合蛋白及其制备和用途
|
|
WO2023072217A1
(en)
*
|
2021-10-28 |
2023-05-04 |
Guangzhou Lintonpharm Co., Ltd. |
Fusion proteins targeting cd3 and cd47
|
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
WO2023079438A1
(en)
|
2021-11-08 |
2023-05-11 |
Pfizer Inc. |
Enhancement of cd47 blockade therapy with anti-vegf agents
|
|
IL313573A
(en)
*
|
2021-12-21 |
2024-08-01 |
Fbd Biologics Ltd |
Transgenic sirpα variants and methods of using them
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4466293A1
(en)
*
|
2022-01-18 |
2024-11-27 |
FBD Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
ES2999273T3
(en)
|
2022-03-17 |
2025-02-25 |
Gilead Sciences Inc |
Ikaros zinc finger family degraders and uses thereof
|
|
US20250257113A1
(en)
*
|
2022-03-24 |
2025-08-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multivalent sirp-alpha fusion polypeptides
|
|
IL315706A
(en)
|
2022-03-24 |
2024-11-01 |
Bitterroot Bio Inc |
Sirp-alpha fusion polypeptides with modified fc domains
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
IL315879A
(en)
*
|
2022-03-25 |
2024-11-01 |
Wuxi Biologics Ireland Ltd |
Anti-her2/anti-cd47 molecules and uses thereof
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CN119487038A
(zh)
|
2022-04-21 |
2025-02-18 |
吉利德科学公司 |
Kras g12d调节化合物
|
|
WO2023213290A1
(en)
*
|
2022-05-06 |
2023-11-09 |
Biosion Inc. |
Recombinant fusion protein targeting cd40 and cd47
|
|
US11807689B1
(en)
*
|
2022-06-01 |
2023-11-07 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
|
US11884740B1
(en)
|
2022-06-01 |
2024-01-30 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
|
US11814439B1
(en)
|
2022-06-01 |
2023-11-14 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
|
US11965032B1
(en)
|
2022-06-01 |
2024-04-23 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
CN116041470B
(zh)
*
|
2022-08-04 |
2024-10-22 |
四川大学华西医院 |
具有高亲和力结合肿瘤细胞cd47的细胞膜材料及其制备方法和应用
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4592316A1
(en)
*
|
2022-09-23 |
2025-07-30 |
Lindis Biotech GmbH |
Isolated antigen-binding protein and use thereof
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN118546255A
(zh)
*
|
2023-02-24 |
2024-08-27 |
恒翼生物医药(上海)股份有限公司 |
一种靶向αvβ3和CD47的双功能融合蛋白以及其应用
|
|
CN121240869A
(zh)
*
|
2023-03-22 |
2025-12-30 |
李望智 |
Sirp变体及其用途
|
|
US20240383922A1
(en)
|
2023-04-11 |
2024-11-21 |
Gilead Sciences, Inc. |
KRAS Modulating Compounds
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
TW202519517A
(zh)
|
2023-07-26 |
2025-05-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|